A case study of a 58-year-old knee patient walks through lean mass loss, sarcopenia risk and tendon changes for people on GLP-1 drugs during rehab.
Recap by typeshit. Post by Facebook on Facebook.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
People who moved from weight loss shots to oral Wegovy lost an average of 4.1% more weight after three months, a finding shared on Facebook.
Dr Nadolsky gives his view on what happens when people come off GLP-1 drugs. The clip itself carries the details, and the caption offers little beyond the topic.
Loading…